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ACR50 criteria with each of the drugs compared. NNTs calcu-
lated as the inverse of the Absolute Risk Reduction, have been
derived using results according to intention-to-treat from a ran-
domised controlled trial (US310) comparing 20 mg daily of
leﬂunomide with 7.15–15 mg weekly of metotrexate, adminis-
tered during 1 year. Considered annual treatment costs related
with the costs of the drug administered the consultations and lab
tests performed for routine monitoring, according to the infor-
mation provided by the manufactures in their summary of
product characteristics. Unitary costs have been obtained from
Spanish cost databases. RESULTS: Using the ACR20 criteria
NNTs with leﬂunomide and metotrexate SC are 4 (95% CI
2.56–7.71) and 5 (95% CI 3.03–14.3) respectively. Using the
ACR50 criteria NNTs are 4 (95% CI 2.72–6.54) and 7 (95% CI
4.03–19.3). The annual cost of each treatment per patient-year
(drugs and monitoring) equals 1793.3€ in case of leﬂunomide
and 2149.2€ for metotrexate SC. Combining these results the
cost of a controlled patient according to ACR20 amounts 7173€
for leﬂunomide and 10,746€ for metotrexate SC. Results accord-
ing to ACR50 equals 7173€ and 15044€ respectively. CONCLU-
SION: From the Spanish National Health System perspective and
effectiveness measured as respondent according to ACR20 the
use of leﬂunomide for patients with Rheumatoid Arthritis could
achieve important cost savings compared with the administration
of metotrexate SC. The savings could be even more important
when the ACR50 response criteria are considered.
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OBJECTIVES: To explore the relationship between dose changes
and costs in rheumatoid arthritis (RA) patients treated with
inﬂiximab. METHODS: A 5-year retrospective study using the
Medstat MarketScan database was conducted. The sample con-
sisted of patients who had a diagnosis of RA (ICD-9 = 714.xx);
at least three administrations of inﬂiximab between 1999 and
2005; no history of using anti-tumor necrosis factors for at least
6-month prior to the index infusion, and continuous enrollment
for at least 12 months after the index infusion. Per-member-per-
month (PMPM) medical and pharmacy costs were compared
among three patient cohorts: increase, decrease, and no change in
dose between the ﬁrst and the last doses in the study period.
Differences in costs were conducted controlling for age, gender,
and a health risk-adjuster score. The cost of adverse events could
not be identiﬁed separately in this analysis. RESULTS: Among
2318 patients included in the study, 685 (29.6%) had decreased
their dose, 627 (27.0%) had no change, and 1006 (43.4%) had
increased their dose during the study. Average age was 57.2
years. Patients in the no-change group were younger than
patients in the other two groups (mean age 55.6 vs. 60.1 and
57.2). Over two-thirds of patients in each group were female.
The no-change group had higher PMPM medical and pharmacy
costs ($2236.90 and $211.94) compared with the increased dose
($1719.80 and $186.09) and decreased dose groups ($1326.90
and $183.64). The difference in PMPM medical costs was sig-
niﬁcant after adjusting for age, gender, and risk score. PMPM
pharmacy costs were not statistically different. CONCLUSION:
Patients with no change in dose had the highest medical costs.
However there were no signiﬁcant differences in pharmacy costs.
Further research to explore the reasons for the differences in
medical costs and the impact of dose changes on clinical and
humanistic outcomes is recommended.
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OBJECTIVES: To evaluate the impact of anti-tumor necrosis
factor (TNF) therapy on health care costs in rheumatoid arthritis
(RA) patients. METHODS: Two groups of patients were identi-
ﬁed using claims data from Blue Cross Blue Shield health plans:
Group A-RA patients who initiated anti-TNF therapy (adali-
mumab, etanercept or inﬂiximab) between January 1, 2003 and
June 30, 2005; Group B-RA patients without anti-TNF therapy.
The groups were matched for gender, age and geographic region
(3 controls: 1 anti-TNF user). The index date for Group A was
deﬁned as the date of ﬁrst anti-TNF therapy; Group B patients
were assigned the index date of their matched case. All patients
were continuously enrolled for >=6 months before and >=12
months after the index date. RA-related and total health care
expenditures, excluding anti-TNF drug cost, were calculated for
the pre- and post-index periods. Multivariate analyses, control-
ling for potential confounders, were performed to compare per-
member-per-month (PMPM) expenditures. RESULTS: In total,
9545 RA patients were included (2405 in Group A and 7140 in
Group B); 70.5% were female and the average age was 48.0
years. In the pre-index period, Group A had higher RA-related
PMPM ($211 versus $32, p < 0.0001) and total health care costs
($711 versus $503, p < 0.0001) than Group B. Compared with
the pre-index period, RA-related PMPM costs (excluding anti-
TNF drugs) decreased for Group A by $44 (-20.9%) but
increased for Group B by $3 (+9.5%) (p = 0.0332) during the
post-index period. After adjusting for confounding variables,
RA-related cost differences from pre- to post-index period
remained between anti-TNF users and controls (p = 0.0049).
CONCLUSION: Although their pre-index RA-related costs were
signiﬁcantly higher, post-index RA-related costs (excluding anti-
TNF drug costs) of RA anti-TNF users decreased signiﬁcantly
from pre-index costs compared with RA non-anti-TNF user
costs. Additional analyses using clinical and quality-of-life
measures are needed to determine the effectiveness of anti-TNF
therapies.
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OBJECTIVES: To evaluate the cost-effectiveness of rituximab
compared to abatacept for the treatment of moderate/severe RA
patients following the failure of one previous TNF-inhibitor from
the perspective of the UK. METHODS: A cost-utility approach
was adopted, evaluating the total direct NHS costs and QALYs.
Baseline patient characteristics were based on the REFLEX phase
III trial. A micro-simulation model of 10,000 RA patients esti-
mated lifetime Health Assessment Questionnaire (HAQ) progres-
sion, QALYs and direct costs. The starting time-point of the
model was upon commencement of treatment with abatacept or
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